Patent 10342792 was granted and assigned to ProLynx on July, 2019 by the United States Patent and Trademark Office.
Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a β-elimination mechanism.